Author:
Liu Jing,Li Xuemei,Shao Yinghong,Guo Xiyun,He Jinggui
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference70 articles.
1. Cancer statistics, 2016;Siegel;CA Cancer J Clin,2016
2. Cancer statistics, 2020;Siegel;CA Cancer J Clin,2020
3. Cancer incidence and mortality in China, 2013;Chen;Cancer Lett,2017
4. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non–small-cell lung cancer in Asia (IPASS);Fukuoka;J Clin Oncol,2011
5. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002);Inoue;Ann Oncol,2012
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献